

# Health Technology Assessment Policy and Methods Review

## Consultation 1 Survey Questions

### Page 1 - Elements and features that are working effectively

Understanding the elements and features of HTA policy and methods that are working effectively, will help to ensure they are preserved and continue to provide positive outcomes for Australians.

Are there any elements and features of HTA policy and methods in Australia that are working effectively?

Yes - there are elements or features that are working effectively and should not change.

Are you able to provide detail of any elements and features of HTA policy and methods that are working effectively? Please use specific details where possible.

Are you able to provide details of positive outcomes resulting from Australia's HTA policies and methods? Please use specific examples where possible.

## Page 2 - Current or future barriers to earliest possible access

Reducing time to access for Australians so that they can access new health technologies as early as possible is recognised as a shared goal of both the Government and Medicines Australia as agreed under clause 5.1 of the Strategic Agreement.

What are the elements and features of HTA policy and methods that are acting as a current barrier to earliest possible access?

Where possible, please detail:

- Specific examples or experiences
- The specific policy, method and/or mechanism that is causing the barrier
- The group/s being impacted
- The magnitude of the impact
- The group/s in the HTA approval pathway contributing to these issues.

What are the elements and features of HTA policy and methods that may act as a future barrier to earliest possible access?

Where possible, please detail:

- Specific examples or experiences
- The specific policy, method and/or mechanism that will cause the barrier
- The group/s impacted
- The magnitude of the impact
- The group/s in the HTA approval pathway contributing to these issues.

Would you like to provide feasible options or suggestions you have to improve elements of HTA policy and methods that are acting as a current or future barrier to earliest possible access?

Where possible, please detail:

- Specific examples or experiences
- The specific policy, method and/or mechanism being suggested
- The group/s in the HTA approval pathway that will need to contribute to the solution
- The outcome the suggestion is expected to achieve
- Any foreseeable risks or negative impacts the suggested change may have and possible ways to mitigate them.

--

## Page 3 - Current or future barriers to equitable access

What are the elements and features of HTA policy and methods that are acting as a current or future barrier to equitable access?

Where possible, please detail:

- Specific examples or experiences
- The specific policy, method and/or mechanism that is causing the barrier
- The group/s being impacted
- The magnitude of the impact
- The group/s in the HTA approval pathway contributing to these issues.

Are you able to provide details of feasible options / suggestions to improve elements of HTA policy and methods that are acting as a current or future barrier to equitable access?

Where possible, please detail:

- Specific examples or experiences
- The specific policy, method and/or mechanism being suggested
- The group/s in the HTA approval pathway that will need to contribute to the solution
- The outcome the suggestion is expected to achieve
- Any foreseeable risks or negative impacts the suggested change may have and possible ways to mitigate them.

## Page 4 - Elements and features that detract from person centredness

Are you able to provide details of any elements and features of HTA policy and methods that may be detracting from person-centeredness?

Where possible, please detail:

- Specific examples or experiences
- The specific policy, method and/or mechanism that is detracting from person-centeredness
- The group/s being impacted
- Details of the impact this is having
- The group/s in the HTA approval pathway contributing to these issues.

Are you able to provide details of feasible options / suggestions to improve elements of HTA policy and methods that are detracting from person-centeredness? Yes

Where possible, please detail:

- Specific examples or experiences
- The specific policy, method and/or mechanism being suggested
- The group/s in the HTA approval pathway that will need to contribute to the solution
- The outcome the suggestion is expected to achieve
- Any foreseeable risks or negative impacts the suggested change may have and possible ways to mitigate them.

## Page 5 - Perverse incentives

HTA helps to ensure equitable and sustainable access to safe, cost-effective, and affordable health technologies for all Australians. A perverse incentive is where an element or feature of HTA policy and methods may be creating an unintended incentive that results in negative consequences.

Are you able to provide details of elements or features of HTA policy and methods that are causing or could cause unintended consequence or perverse incentives?

Where possible, please detail:

- Specific examples or experiences
- The specific policy, method and/or mechanism creating the perverse incentive
- Details of the unintended outcome occurring or that could occur
- The group/s contributing to these issues.

Are you able to provide details of feasible options / suggestions to improve elements of HTA policy and methods that are creating unintended outcomes or perverse incentives either currently or in the future?

Where possible, please detail:

- Specific examples or experiences
- The specific policy, method and/or mechanism being suggested
- The outcome the suggestion is expected to achieve
- The group/s that will need to contribute to the solution.
- Any foreseeable risks or negative impacts the suggested change may have and possible ways to mitigate them?

# Page 6 - Areas for further investigation or analysis

Under section 5.3 of the Strategic Agreement it was agreed that an expert in HTA would be engaged, to undertake an analysis of current methods used by the PBAC, contemporary research and relevant methodologies and purchasing practices used by comparable international jurisdictions as guided by the terms of reference.

Draft versions of initial findings from this analysis will be available to stakeholders through Consultation 2 later in the year.

Noting the overall scope of the analysis from the HTA expert will be in line with the ToR and agreed by the Reference Committee, are there any HTA or reimbursement models, or elements thereof, utilised in other countries that you believe should be considered for potential adoption in Australia, or that it would be good for the Reference Committee to understand?

Where possible, please provide:

1 - Country / Jurisdiction

2 - Details of:

- Which elements of the HTA policy, method, mechanism for suggested for consideration
- Any outcomes that the suggestion is achieving that should be considered
- Any unintended consequences that the suggestion is having or may have if adapted in Australia

Country / Jurisdiction:

Details of: Which elements of the HTA policy, method, mechanism for suggested for consideration; Any outcomes that the suggestion is achieving that should be considered; Any unintended consequences that the suggestion is having or may have if adapted in Australia

--



## Page 7 - Other details of importance to the HTA Policy and Methods Review not covered above + document / attachment upload point.

The HTA Review [terms of reference](#) sets out:

- the background to the HTA Review
- how the HTA Review will take account of recent and concurrent reform processes that impact HTA
- HTA Review objectives
- areas under consideration by the HTA Review.

Noting the objectives of the review set out in the Terms of Reference, is there any other information relevant to the Review not provided above that you would like to add?

Would you like to upload any attachments/supporting evidence to your submission?

*(File upload point)*